Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasia

Examination the efficacy of Mirabegron on patient with overactive bladder after treatment with a1 blocker for benign prostatic hyperplasia - Examination the efficacy of Mirabegron on patient with a1 blocker resistance overactive bladder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019735

Enrollment

100

Registered

2015-11-10

Start date

2015-11-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

prescribe Mirabegron for 12 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Overactive bladder after treatment of BPH

Exclusion criteria

Exclusion criteria: suspect of malignancy contraindication of Mirabegron using other anticholinergic agent using A1 blocker within 4 weeks using Dutasteride redidual urine over 50mL urinary infection

Design outcomes

Primary

Measure	Time frame
OABSS after twelve weeks	—

Countries

Japan

Contacts

Public ContactTeruhiko Tsuru

Shiga University of medical Science Urology

tsuru@belle.shiga-med.ac.jp0775482273

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026